Advertise on podcast: CEimpact Podcast

With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Reemal Zaheer, PharmD, CSP Pharmacist Johns Hopkins Medicine GAMECHANGERS CLINICAL UPDATE SERIES The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCE Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.   CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Explain the role of biosimilars in the treatment of inflammatory conditions. 2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies. Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 Hr UAN: 0107-0000-26-045-H01-P Initial release date: 2/2/2026 Expiration date: 2/2/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Erin Raney, PharmD Professor Midwestern University College of Pharmacy GAMECHANGERS CLINICAL UPDATE SERIES The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCE Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.   CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy. 2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy. Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 Hr UAN: 0107-0000-26-044-H01-P Initial release date: 1/26/2026 Expiration date: 1/26/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram Follow CEimpact on Social Media: LinkedIn Instagram

Ranitidine — once withdrawn from the market over safety concerns — was recently re‑approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product's changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST K. Ashley Garling-Nanez, PharmD Assistant Director of Program UT Center of Health Communications GAMECHANGERS CLINICAL UPDATE SERIES The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCE Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Summarize the major safety and regulatory issues that prompted ranitidine's withdrawal, and the changes made in the reformulated product approved in 2025. 2. Describe pharmacist‑relevant considerations for dispensing, patient counseling, and transition from alternative acid‑reducing therapies. Rachel Maynard and K. Ashley Garling-Nanez have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 Hr UAN: 0107-0000-26-043-H01-P Initial release date: 1/19/2026 Expiration date: 1/19/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Christina O'Connor, PharmD, BCPS, BCIDP Clinical Pharmacy Manager Mayo Clinic GAMECHANGERS CLINICAL UPDATE SERIES The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCE Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence. 2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education. Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose. 0.075 CEU/0.75 Hr UAN: 0107-0000-26-038-H01-P Initial release date: 1/12/2026 Expiration date: 1/12/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Corticosteroids in the treatment of community-acquired pneumonia (CAP) remain a topic of clinical curiosity and mixed opinions. In this unique episode, two expert guests share opposing perspectives—one advocating for corticosteroid use in CAP and the other urging caution—offering pharmacists a balanced view of the current evidence and practice considerations. Tune in to explore both sides of the debate and walk away with insights to inform your role in collaborative patient care. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUESTS Sam Markle, PharmD Critical Care Pharmacist Sanford Health Tristan Houle, PharmD PGY2 Critical Care Pharmacy Resident Sanford Health PRACTICE RESOURCE Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current evidence supporting and challenging the use of corticosteroids in the treatment of community-acquired pneumonia (CAP). 2. Identify key considerations for pharmacists when evaluating corticosteroid use as adjunctive therapy in CAP. Rachel Maynard, Sam Markle, and Tristan Houle have no relevant financial relationships to disclose. 0.05 CEU/0.5 Hr UAN: 0107-0000-26-032-H01-P Initial release date: 1/5/2026 Expiration date: 1/5/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

As cannabis becomes more widely available and socially accepted, so does the misconception that it's safe to use during pregnancy and lactation. This course reviews updated guidance from the American College of Obstetricians and Gynecologists (ACOG), highlighting the evidence behind the risks and outlining how pharmacists can address misinformation and counsel patients effectively. You will learn how to support safe, informed decision-making that promotes the health of both parent and child. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Kevin Shea, PharmD Pharmacist  Vytal Options  PRACTICE RESOURCE Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Identify current ACOG recommendations regarding cannabis use during pregnancy and lactation. 2. Describe pharmacist strategies for screening, counseling, and reducing risks associated with cannabis use during the perinatal period. Rachel Maynard and Kevin Shea have no relevant financial relationships to disclose. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-377-H01-P Initial release date: 12/29/2025 Expiration date: 12/29/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Recent preclinical studies highlight the potential of micro‑dosed lithium to modulate Alzheimer’s disease pathology and support neuronal health. This episode examines the molecular mechanisms, current evidence in Alzheimer’s models, and emerging considerations for safe use and monitoring. You will gain insights to navigate this evolving topic and support informed discussions around lithium micro‑dosing in Alzheimer’s care. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Dawn Gerber, PharmD, BCGP, FASCP, FAzPA, CPAFH Professor of Pharmacy Practice Midwestern University PRACTICE RESOURCE Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current evidence on the use of microdose lithium in Alzheimer's disease. 2. Identify pharmacist considerations for monitoring, patient selection, and safety in the context of lithium micro-dosing for Alzheimer's. Rachel Maynard and Dawn Gerber have no relevant financial relationships to disclose. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-375-H01-P Initial release date: 12/22/2025 Expiration date: 12/22/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Patients with fibromyalgia have waited more than a decade for a new therapeutic option, and a recent regulatory approval signals a shift for these patients. This episode reviews the clinical trial data, mechanism of action, dosing considerations, and pharmacist‑relevant monitoring for the newly approved sublingual formulation of cyclobenzaprine HCl. You will gain practical insights to inform patient education, therapy optimization, and interdisciplinary collaboration in fibromyalgia care. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Amanda (Mandy) Mullins, PharmD, BCPS Clinical Pharmacist Practitioner Veterans Affairs PRACTICE RESOURCE Purchase this course to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe the mechanism of action and key clinical trial outcomes associated with the newly approved prescription medication for fibromyalgia. 2. Identify pharmacist responsibilities for dosing, monitoring adverse effects, and patient counseling when supporting the use of this new fibromyalgia therapy. Rachel Maynard and Amanda (Mandy) Mullins have no relevant financial relationships with ineligible companies to disclose.  0.05 CEU/0.5 Hr UAN: 0107-0000-25-371-H01-P Initial release date: 12/15/2025 Expiration date: 12/15/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls Hunter O. Rondeau, PharmD, BCIDP, AAHIVP Antimicrobial Stewardship Coordinator, SSM Health Adjunct Clinical Assistant Professor, University of Kansas School of Pharmacy Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.  Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance. 2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-372-H01-P Initial release date: 12/8/2025 Expiration date: 12/8/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Recent FDA actions have brought renewed attention to leucovorin as a potential treatment for managing symptoms associated with autism spectrum disorder. This course explores the clinical distinctions between autism and cerebral folate deficiency, reviews key evidence behind leucovorin use, and outlines counseling considerations relevant to pharmacy practice. You will gain clarity on this complex and evolving topic to better support informed, evidence-based care. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Geoff Wall, PharmD, FCCP, BCPS Professor of Pharmacy Practice Iowa Methodist Medical Center Rachel Maynard and Geoff Wall have no relevant financial relationships to disclose.     CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe current clinical evidence related to the use of leucovorin in autism and cerebral folate deficiency. 2. Identify key counseling considerations for pharmacists discussing leucovorin therapy with patients and caregivers. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-363-H01-P Initial release date: 12/1/2025 Expiration date: 12/1/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Pharmacists play a critical role in infectious disease care, and staying up to date on antibiotic therapies is key to ensuring optimal patient outcomes. This episode reviews recently FDA-approved antibiotics, offers a practical refresher on commonly used antibiotic classes, and highlights frequent side effects—along with strategies for managing them in practice. Tune in to strengthen your clinical knowledge and support safe, effective antibiotic use across care settings. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Hunter Rondeau, PharmD, BCIDP, AAHIVP Antimicrobial Stewardship Coordinator SSM Health Joshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose.  Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.    CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Identify newly FDA-approved antibiotics and their clinical indications. 2. Describe commonly used antibiotic classes, their typical side effects, and strategies to manage or mitigate those effects. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-362-H01-P Initial release date: 11/24/2025 Expiration date: 11/24/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Discover the benefits of implementing a long-acting injectable (LAI) service at your pharmacy practice site and the impact this service can have on patient care and outcomes. Listen to this week’s episode and learn how to elevate your pharmacy services!   HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Lindsay McCoy, PharmD, BCPP Pharmacy Manager Village Drug Shop at Advantage CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Analyze the benefits and challenges of implementing a long-acting injectable (LAI) service in a pharmacy practice site. 2. Discuss how an LAI service can improve patient care, increase financial sustainability, and optimize patient outcomes. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-354-H01-P Initial release date: 11/17/2025 Expiration date: 11/17/2026 Additional CPE details can be found here. Take your pharmacy practice to the next level with our comprehensive course on the administration of long-acting injectables: Pharmacy-Based Administration of Long-Acting Injectables: A Sharp Idea 4 hours  |  On Demand Explore a cutting edge clinical service opportunity with this collection of courses specifically designed to equip pharmacists with the knowledge and skills necessary for the effective management and administration of long-acting injectable medications (LAIs). Course content explores diverse drug profiles, advanced administration techniques, and the strategic implementation of LAI-related services to support the needs of your patients and communities. Follow CEimpact on Social Media: LinkedIn Instagram

Opioids remain a cornerstone of palliative care for patients with serious illnesses like cancer, yet their use is often misunderstood, undertreated, or approached with unnecessary hesitation. This episode explores what pharmacists need to know about assessing opioid appropriateness, questioning therapy when warranted, and supporting comfort-focused care within established clinical and ethical standards. Tune in to build confidence in your role and contribute meaningfully to the care of patients facing serious illness. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Lorin Fisher, PharmD, BCACP Clinical Assistant Professor University of Iowa College of Pharmacy Joshua Davis Kinsey and Lorin Fisher have no relevant financial relationships to disclose. CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:  If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Identify the role of opioids in managing pain and other symptoms for patients receiving palliative care. 2. Describe key considerations for evaluating opioid prescriptions in the context of serious illness, including appropriate use and safety concerns. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-330-H01-P Initial release date: 11/10/2025 Expiration date: 11/10/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

Respiratory syncytial virus (RSV) continues to pose a serious health threat—particularly to infants, older adults, and immunocompromised individuals—making it critical for pharmacy professionals to stay up to date on prevention and treatment options. This episode covers the latest FDA-approved RSV therapies, including vaccines and monoclonal antibodies, while highlighting clinical pearls for use across care settings. Tune in to stay informed and better support patients during the upcoming respiratory season. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Kalen Manasco, PharmD, BCPS, BCPPS, FCCP, FPPA Professor University of Florida College of Pharmacy Joshua Davis Kinsey and Kalen Manasco have no relevant financial relationships with ineligible companies to disclose.  Pharmacist Members, REDEEM YOUR CPE HERE!   Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode) CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Differentiate between RSV vaccines and monoclonal antibody therapies, including their indications and target patient populations. 2. Identify key counseling points and administration considerations associated with currently available RSV vaccines and monoclonal antibody therapies. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-312-H01-P Initial release date: 11/3/2025 Expiration date: 11/3/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram

GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information. HOST Joshua Davis Kinsey, PharmD VP, Education CEimpact GUEST Jamie Pitlick, PharmD, BCPS, BC-ADM Professor and Chair of Pharmacy Practice Drake University College of Pharmacy and Health Sciences Joshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.   CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.  CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders. 2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health. 0.05 CEU/0.5 Hr UAN: 0107-0000-25-311-H01-P Initial release date: 10/27/2025 Expiration date: 10/27/2026 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram